scholarly journals RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)

2020 ◽  
pp. 1-7
Author(s):  
S. Walter ◽  
T.B. Clanton ◽  
O.G. Langford ◽  
M.S. Rafii ◽  
E.J. Shaffer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Effective Means ◽  
Web Based ◽  
The Us ◽  
Study Team ◽  
Prodromal Alzheimer’S Disease ◽  
Prevention Trials ◽  
Study Participants ◽  
The Impact

BACKGROUND: The Alzheimer Prevention Trials (APT) Webstudy is the first stage in establishing a Trial-ready Cohort for Preclinical and Prodromal Alzheimer’s disease (TRC-PAD). This paper describes recruitment approaches for the APT Webstudy. Objectives: To remotely enroll a cohort of individuals into a web-based longitudinal observational study. Participants are followed quarterly with brief cognitive and functional assessments, and referred to Sites for in-clinic testing and biomarker confirmation prior to enrolling in the Trial-ready Cohort (TRC). Design: Participants are referred to the APT Webstudy from existing registries of individuals interested in brain health and Alzheimer’s disease research, as well as through central and site recruitment efforts. The study team utilizes Urchin Tracking Modules (UTM) codes to better understand the impact of electronic recruitment methods. Setting: A remotely enrolled online study. Participants: Volunteers who are at least 50 years old and interested in Alzheimer’s research. Measurements: Demographics and recruitment source of participant where measured by UTM. Results: 30,650 participants consented to the APT Webstudy as of April 2020, with 69.7% resulting from referrals from online registries. Emails sent by the registry to participants were the most effective means of recruitment. Participants are distributed across the US, and the demographics of the APT Webstudy reflect the referral registries, with 73.1% female, 85.0% highly educated, and 92.5% Caucasian. Conclusions: We have demonstrated the feasibility of enrolling a remote web-based study utilizing existing registries as a primary referral source. The next priority of the study team is to engage in recruitment initiatives that will improve the diversity of the cohort, towards the goal of clinical trials that better represent the US population.

P2-066: Web-based application to estimate and project the burden of Alzheimer's disease and evaluate the impact of potential interventions

2009 ◽  
Vol 5 (4S_Part_9) ◽  
pp. P281-P281
Author(s):  
Elizabeth Colantuoni ◽  
Andre Hackman ◽  
Ron Brookmeyer ◽  
H. Michael Arrighi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Web Based ◽  
The Impact

scholarly journals THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW

2020 ◽  
pp. 1-5
Author(s):  
P.S. Aisen ◽  
R.A. Sperling ◽  
J. Cummings ◽  
M.C. Donohue ◽  
O. Langford ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
Amyloid Peptide ◽  
Collaborative Effort ◽  
Web Based ◽  
Initial Validation ◽  
Clinically Normal ◽  
Prodromal Alzheimer’S Disease ◽  
Apolipoprotein E Genotype

The Trial-Ready Cohort for Preclinical/prodromal Alzheimer’s Disease (TRC-PAD) project is a collaborative effort to establish an efficient mechanism for recruiting participants into very early stage Alzheimer’s disease trials. Clinically normal and mildly symptomatic individuals are followed longitudinally in a web-based component called the Alzheimer’s Prevention Trial Webstudy (APT Webstudy), with quarterly assessment of cognition and subjective concerns. The Webstudy data is used to predict the likelihood of brain amyloid elevation; individuals at relatively high risk are invited for in-person assessment in the TRC screeing phase, during which a cognitive battery is administered and Apolipoprotein E genotype is obtained followed by reassessment of risk of amyloid elevation. After an initial validation study, plasma amyloid peptide ratios will be included in this risk assessment. Based on this second risk calculation, individuals may have amyloid testing by PET scan or lumbar puncture, with those potentially eligible for trials followed in the TRC, while the rest are invited to remain in the APT Webstudy. To date, over 30,000 individuals have participated in the Webstudy; enrollment in the TRC is in its early stage.

scholarly journals The impact of a nutritional intervention in prodromal Alzheimer’s disease: The LipiDiDiet clinical trial

2020 ◽  
Vol 16 (S10) ◽  
Author(s):  
Tobias Hartmann ◽  
Alina Solomon ◽  
Pieter Jelle Visser ◽  
Suzanne B Hendrix ◽  
Kaj Blennow ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Nutritional Intervention ◽  
Prodromal Alzheimer’S Disease ◽  
The Impact

scholarly journals Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways

2011 ◽  
Vol 2011 ◽  
pp. 1-14 ◽  
Author(s):  
Paolo Olgiati ◽  
Antonis M. Politis ◽  
George N. Papadimitriou ◽  
Diana De Ronchi ◽  
Alessandro Serretti
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Intracellular Transport ◽  
Cholesterol Metabolism ◽  
Late Onset ◽  
Meta Analysis ◽  
Level Of Evidence ◽  
Systematic Analysis ◽  
Web Based ◽  
The Impact

The genetics of late-onset Alzheimer's disease (LOAD) has taken impressive steps forwards in the last few years. To date, more than six-hundred genes have been linked to the disorder. However, only a minority of them are supported by a sufficient level of evidence. This review focused on such genes and analyzed shared biological pathways. Genetic markers were selected from a web-based collection (Alzgene). For each SNP in the database, it was possible to perform a meta-analysis. The quality of studies was assessed using criteria such as size of research samples, heterogeneity across studies, and protection from publication bias. This produced a list of 15 top-rated genes:APOE, CLU, PICALM, EXOC3L2, BIN1, CR1, SORL1, TNK1, IL8, LDLR, CST3, CHRNB2, SORCS1, TNF,andCCR2.A systematic analysis of gene ontology terms associated with each marker showed that most genes were implicated in cholesterol metabolism, intracellular transport of beta-amyloid precursor, and autophagy of damaged organelles. Moreover, the impact of these genes on complement cascade and cytokine production highlights the role of inflammatory response in AD pathogenesis. Gene-gene and gene-environment interactions are prominent issues in AD genetics, but they are not specifically featured in the Alzgene database.

scholarly journals HARNESSING TECHNOLOGY TO SUPPORT PERSONS WITH DEMENTIA AND THEIR CAREGIVERS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S389-S389
Author(s):  
Stacy L Andersen ◽  
Walter Boot ◽  
Jeffrey Kaye
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Group Intervention ◽  
Financial Strain ◽  
Loss Of Function ◽  
The Us ◽  
Skin Conductivity ◽  
The Individual ◽  
Virtual Support ◽  
The Impact

Abstract One in eight older adults in the US has Alzheimer’s disease or a related dementia, which are characterized by progressive cognitive and physical declines. The impact of dementia also goes beyond the individual since 92% of persons with dementia receive functional and emotional support from family members and other informal caregivers. The time demands, financial strain, and emotional toll of caregiving are known to cause increased stress and health problems. Therefore, there is a wealth of opportunities to develop new ways to intervene in the progressive loss of function among persons with dementia and ways to support them and their caregivers. Co-sponsored by the Alzheimer’s Disease and Related Dementias and Technology and Aging Interest Groups, this symposium addresses innovations in the implementation of new and existing technologies in the dementia care continuum. We will discuss the development and testing of a new mobile application designed to integrate both physical activity and cognitive training. Then we will discuss results from a virtual support group intervention to provide disease education, care planning, and emotional and social support among persons newly diagnosed with Alzheimer’s disease and living alone. Next we will share results from a study using customized voice-assisted technologies to enable individuals with memory impairment to maintain independence and quality of life and reduce caregiver burden. Finally, we will present findings regarding the validity and accuracy of a wearable sensor-based device that measures skin conductivity and heart rate variability to monitor stress level among caregivers of persons with dementia.

The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US

2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
A Brennan ◽  
B Nagy ◽  
A Brandtmüller ◽  
SK Thomas ◽  
M Gallagher ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Utility ◽  
Transdermal Patch ◽  
The Us ◽  
The Cost

Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer’s Disease Mice

2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Dendritic Spine ◽  
Early Stage ◽  
Learning Ability ◽  
Middle Aged ◽  
Protein Levels ◽  
Spine Pathology ◽  
The Impact

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.

Sign in / Sign up

Export Citation Format

Share Document